A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer
The EU project GANNET53 is a clinical trial with 18 partners from Austria, Germany, Belgium and France.
Within the context of this clinical trial, the efficacy and safety of a new drug (ganetespib) in combination with standard chemotherapy (paclitaxel) is tested. The drug ganetespib is a targeted therapy and works against a central genetic alteration, which is often seen in tumours of patients with epithelial ovarian, fallopian tube or peritoneal cancer, i.e. genetically altered (mutant) p53 protein.
The healthy, unaltered protein p53 protects the body's cells from the development of cancer. Its key functions are the basic mechanisms of human cells such as cell division, cell repair, cell aging and cell death. In case of a permanent alteration (mutation), it loses its protective function and, as a consequence, also damaged cells can divide uncontrollably which can lead to the development of cancer. Latest scientific results have already shown that by the drug ganetespib the altered (mutant) p53 protein can successfully be fought in cancer cells.
In the clinical trial GANNET53, this new drug ganetespib is used in combination with the chemotherapy paclitaxel in a specific subgroup of patients with ovarian, fallopian tube or peritoneal cancer. These are patients whose disease has recurred following the primary treatment and who now no longer respond to the standard therapy (chemotherapy containing platinum). The objective of this clinical trial is to improve the prognosis of these patients and their quality of life.
MedUni Vienna Researchers
The Medical University of Vienna is project partner under the leadership of Ao.Univ.-Prof. Dr. Robert Zeilinger, Department of Obstetrics and Gynecology.
Project coordinator: Prof. Nicole Concin, Medical University of Innsbruck, Austria.
18 project partners
|Funding Volume, Medical University of Vienna||465.989 €|
|Funding Volume, Total||5.994.072 €|